Latest Hotspot

Pfizer Announces Positive Phase III Results for ADCETRIS® in Treating Resistant Large B-cell Lymphoma

15 March 2024
3 min read

Pfizer Inc. has declared that their recent Phase 3 clinical trial involving ADCETRIS® (brentuximab vedotin) used in tandem with the medications lenalidomide and rituximab for patients suffering from relapsed or refractory diffuse large B-cell lymphoma has yielded profound and statistically substantial enhancements in patient longevity. This improvement is notably superior when compared to the combination of lenalidomide, rituximab, and a placebo.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The profile of ADCETRIS' safety and tolerability observed in the ECHELON-3 study aligns with previous outcomes noted for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who were administered ADCETRIS in past clinical research. The comprehensive outcomes are slated to be disclosed during a future healthcare conference.

Roger Dansey, M.D., Pfizer's Chief Development Officer in Oncology, expressed his enthusiasm, "With this being our third Phase 3 research showing a survival advantage for a regimen including ADCETRIS in a certain lymphoma subset, we are hopeful about ADCETRIS' potential to fulfill a significant treatment void for individuals with relapsed or refractory DLBCL, irrespective of CD30 levels."

Dr. Dansey remarked on the promising nature of the findings, emphasizing that the participant pool consisted of patients who had undergone extensive previous treatments, with some having had former CAR-T therapy.

As the predominant lymphoma variant, DLBCL is characterized by rapid progression and is considered a highly aggressive hematological malignancy. Post-initial therapy, around 40% of DLBCL patients either do not achieve a response or encounter disease recurrence.

In the realm of lymphoma care, ADCETRIS is established as a therapeutic staple and boasts seven sanctioned uses within the United States, having been administered to upwards of 55,000 individuals since its inaugural U.S. approval over a decade ago in 2011. The global patient reach for ADCETRIS treatment has exceeded 140,000. Following the ECHELON-3 findings, Pfizer intends to engage with the U.S. Food and Drug Administration regarding potential support for a regulatory submission in the United States.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of March 14, 2024, there are 4 investigational drugs for the CD30 and Tubulin target, including 88 indications, 15 R&D institutions involved, with related clinical trials reaching 1605, and as many as 596 patents.

Brentuximab Vedotin is an ADC drug that targets CD30 and Tubulin. It has been approved for the treatment of numerous neoplasms and other diseases. Its approval in multiple countries, including the United States and China, demonstrates its potential as a valuable therapeutic option in the field of biomedicine.

图形用户界面, 文本

描述已自动生成

Atai Strategic Investment in Beckley Psytech to Jointly Develop Rapid-Acting Psychedelic Medications for the Treatment of Depression
DrugDeal Decode
5 min read
Atai Strategic Investment in Beckley Psytech to Jointly Develop Rapid-Acting Psychedelic Medications for the Treatment of Depression
15 March 2024
clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.
Read →
Longbio Pharma Presents Promising LP-003 Drug Data at AAD 2024
Latest Hotspot
3 min read
Longbio Pharma Presents Promising LP-003 Drug Data at AAD 2024
15 March 2024
At the 2024 AAD conference, Longbio Pharma showcased encouraging early-stage findings for their drug LP-003.
Read →
Navigating Health Information: How to Use Synapse to Search for Fenofibrate
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Fenofibrate
15 March 2024
Fenofibrate, the small molecule drug, possesses a unique ability to target the peroxisome proliferator-activated receptor alpha (PPARα) as an agonist.
Read →
10xBio's Phase 2b Trial Suggests Improved Submental Fat Treatment
Latest Hotspot
3 min read
10xBio's Phase 2b Trial Suggests Improved Submental Fat Treatment
15 March 2024
10xBio Reveals Interim Phase 2b Trial Outcomes Indicate Enhanced Effectiveness of New Treatment in Submental Fat Reduction.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.